Inhibition of p38 MAP kinase attenuates left ventricular hypertrophy and inhibits progression of systolic dysfunction on pressure-overload induced pathological cardiac hypertrophy in mice

DOI IR HANDLE Web Site
  • Hanada Kenji
    Department of Cardiology, Hirosaki University Graduate School of Medicine
  • Osanai Tomohiro
    Department of Cardiology, Hirosaki University Graduate School of Medicine
  • Sukekawa Takanori
    Department of Cardiology, Hirosaki University Graduate School of Medicine
  • Ohya Fumie
    Department of Cardiology, Hirosaki University Graduate School of Medicine
  • Izumiyama Kei
    Department of Cardiology, Hirosaki University Graduate School of Medicine
  • Sagara Shigeki
    Department of Cardiology, Hirosaki University Graduate School of Medicine
  • Ito Taihei
    Department of Cardiology, Hirosaki University Graduate School of Medicine
  • Yamamoto Yuko
    Department of Cardiology, Hirosaki University Graduate School of Medicine
  • Shibutani Shuji
    Department of Cardiology, Hirosaki University Graduate School of Medicine
  • Tomita Hirofumi
    Department of Cardiology, Hirosaki University Graduate School of Medicine
  • Okumura Ken
    Department of Cardiology, Hirosaki University Graduate School of Medicine

Bibliographic Information

Other Title
  • p38 MAP kinase の抑制はマウスの圧負荷による病的心肥大を軽減し心機能低下を抑制する

Search this article

Abstract

Background: P38 mitogen-activated protein kinase (MAP kinase) plays on important role for progression of pathological cardiac hypertrophy. However, the role of p38 MAP kinase in cardiac hypertrophy induced by pressure overload remains unclear. We investigated the effect of chronic treatment with p38 MAP kinase inhibitor on the development of heart failure induced by transverse aortic constriction (TAC) in mice.<br> Methods and Results: TAC increased left ventricular septal wall thickness (LVSWT) and cross-sectional area (CSA) of cardiomyocyte, and decreased LV fractional shortening (FS) compared with sham operation after 6 weeks. TAC also increased phosphorylation of p38 MAP kinase, whereas other hypertrophic signals were unchanged. In another experiment, TAC mice and sham operated mice were treated with subcutaneous injection of p38 MAP kinase inhibitor SB202190 (5mg/kg/day) or placebo five times a week for six weeks. Treatment with p38 MAP kinase inhibitor attenuated the increase in LVSWT and CSA, and the decrease in FS in mice with TAC.<br> Conclusions: Inhibition of p38 MAP kinase attenuated left ventricular hypertrophy and inhibited progression of systolic dysfunction in pressure overload-induced cardiac hypertrophy. These results suggest that inhibition of p38 MAP kinase has a protective effect for development of heart failure induced by pressure overload.

Journal

  • Hirosaki Medical Journal

    Hirosaki Medical Journal 62 (1), 18-26, 2011

    Hirosaki University Graduate School of Medicine,Hirosaki Medical Society

Keywords

Details 詳細情報について

Report a problem

Back to top